Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177lu-rad204
- Development stage
- Phase 1
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177lu-rad204 is a radiopharmaceutical composed of a single-domain monoclonal antibody (nanobody) targeting programmed cell death ligand 1 (PD-L1; CD274), conjugated to the beta-emitting radioisotope lutetium-177. The drug is designed for targeted radioimmunotherapy of solid tumors that overexpress PD-L1. By binding to PD-L1 on tumor cells, the nanobody delivers localized radiation from lutetium-177 directly to cancer cells while sparing surrounding healthy tissue. This approach aims to overcome resistance mechanisms associated with current standard-of-care immunotherapies and may be effective in multiple tumor types including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), and endometrial carcinoma[1][3][5].
- Other names
- lutetium Lu 177 anti-PD-L1 nanobody RAD204
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on 177lu-rad204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177lu-rad204.